Trials / Completed
CompletedNCT02647112
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma
Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,050 (actual)
- Sponsor
- Nucleix Ltd. · Industry
- Sex
- All
- Age
- 22 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology.
Detailed description
Clinical trial to determine the performance characteristics (sensitivity and specificity) of the Bladder EpiCheck test compared to the gold standard cystoscopy and pathology in patients under monitoring for reccurrence of bladder cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Bladder EpiCheck | Urine test for the monitoring of bladder cancer recurrence |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2016-01-06
- Last updated
- 2021-05-04
Locations
6 sites across 4 countries: Germany, Israel, Netherlands, Spain
Source: ClinicalTrials.gov record NCT02647112. Inclusion in this directory is not an endorsement.